- 专利标题： Anti-CD25 for tumour specific cell depletion
-
申请号： US16979935申请日： 2019-03-13
-
公开(公告)号： US11697688B2公开(公告)日： 2023-07-11
- 发明人: Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
- 申请人： Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- 申请人地址： GB Hertfordshire
- 专利权人： Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- 当前专利权人： Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- 当前专利权人地址： GB Hertfordshire; GB London
- 代理机构： Choate, Hall & Stewart LLP
- 代理商 Brenda Herschbach Jarrell; Michael L. Vetter
- 优先权： GB 04027 2018.03.13 GB 04028 2018.03.13 GB 04029 2018.03.13 WO TEP201856312 2018.03.13
- 国际申请： PCT/EP2019/056248 2019.03.13
- 国际公布： WO2019/175216A 2019.09.19
- 进入国家日期： 2020-09-11
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61P35/02 ; C12N15/85 ; A61P35/00 ; A61K39/395 ; C07K14/55 ; A61K45/06 ; A61K39/00
摘要：
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
公开/授权文献
- US20210009704A1 ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION 公开/授权日：2021-01-14
信息查询
